| Drug General Information |
| Drug ID |
D0P6DJ
|
| Former ID |
DNC005636
|
| Drug Name |
VATALANIB
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 2 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H15ClN4
|
| InChI |
InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
|
| InChIKey |
YCOYDOIWSSHVCK-UHFFFAOYSA-N
|
| CAS Number |
CAS 212141-54-3
|
| PubChem Compound ID |
|
| PubChem Substance ID |
8034494, 10318716, 11544568, 14827532, 46227754, 47207942, 50070546, 50071177, 50100112, 53790491, 57347324, 58107197, 77174846, 91616548, 92308747, 93619729, 93692965, 103317292, 103905548, 104171421, 104430401, 121264549, 125344798, 126652555, 126681092, 127342265, 127342266, 129776330, 131305145, 134339000, 134342841, 135141434, 136367735, 137001820, 142433490, 144206361, 152035902, 162187512, 162814431, 163790606, 164041949, 164235383, 164766095, 164830894, 165222126, 165238043, 165998596, 170466113, 172916394, 175426883
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 3 |
Target Info |
Inhibitor |
[3]
|
|---|
| Epidermal growth factor receptor |
Target Info |
Inhibitor |
[4]
|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[4]
|
| mRNA of VEGFR1 |
Target Info |
Inhibitor |
[5]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesionhsa04010:MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
Dorso-ventral axis formation
|
|
Focal adhesion
|
|
Adherens junction
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Hepatitis C
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04014:Ras signaling pathway
|
|
VEGF signaling pathway
|
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
TNFalpha Signaling PathwayNetPath_16:IL4 Signaling Pathway
|
|
EGFR1 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Cadherin signaling pathway
|
|
EGF receptor signaling pathwayP00005:Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
VEGF and VEGFR signaling network
|
|
VEGFR3 signaling in lymphatic endotheliumlysophospholipid_pathway:LPA receptor mediated events
|
|
Signaling events mediated by PTP1B
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
Regulation of Telomerase
|
|
EGF receptor (ErbB1) signaling pathway
|
|
EGFR-dependent Endothelin signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
E-cadherin signaling in keratinocytes
|
|
ErbB receptor signaling network
|
|
Internalization of ErbB1
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
Syndecan-3-mediated signaling eventshif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
S1P1 pathway
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network
|
|
HIF-2-alpha transcription factor network
|
|
S1P3 pathway
|
|
VEGFR1 specific signals
|
|
Reactome
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in EGFR signaling
|
|
GAB1 signalosome
|
|
SHC1 events in EGFR signaling
|
|
EGFR downregulation
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
EGFR Transactivation by Gastrin
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Constitutive Signaling by EGFRvIII
|
|
RAF/MAP kinase cascadeR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
WikiPathways
|
Signaling by VEGFWP673:ErbB Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
Focal Adhesion
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
|
Bladder Cancer
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Signaling by ERBB4
|
|
Signaling by ERBB2
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
PIP3 activates AKT signaling
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Aryl Hydrocarbon Receptor
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Gastric cancer network 2
|
|
AGE/RAGE pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by EGFR
|
|
L1CAM interactionsWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP306:Focal Adhesion
|
|
Angiogenesis
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00348790) Vatalanib in Treating Patients With Recurrent or Progressive Meningioma. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5705). |
|---|
| REF 3 | J Med Chem. 2005 Mar 10;48(5):1610-9.Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. |
|---|
| REF 4 | Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. Epub 2007 Mar 23.Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
|---|
| REF 5 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9. Epub 2006 Feb 3.Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
|---|
